COVID-19 pandemic restrictions.

This trial will compare the efficacy and tolerability of 10 Hz vs. 1 Hz vs. sham repetitive transcranial magnetic stimulation targeting the dorsomedial prefrontal cortex, delivered once daily over 30 days, in patients with a diagnosis of bulimia or anorexia nervosa binge-purge subtype. The trial will include structural and functional MRI, and behavioral measures obtained before, during, and after treatment.

Inclusion Criteria (Patient):

• Voluntary and Competent to Consent
• MINI confirmed Diagnosis of Bulimia Nervosa OR Anorexia Nervosa, Binge/Purge subtype
• Outpatient
• Between the ages of 18-65
• Have had no increase or initiation of any psychotropic medication in the last 4 weeks prior to screening
• Must adhere to research schedule.
• Pass the TMS Safety Screening Questionnaire.
• Failed to achieve a clinical response to at least one pharmacotherapy or behavioral treatment in the current episode.

Exclusion Criteria (Patient):

• Have a concomitant major unstable medical illness, cardiac pacemaker or implanted medical pump
• Have active suicidal intent
• Are pregnant
• Have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms
• Have a MINI diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia assessed by a study investigator to be primary and causing greater impairment than the ED
• Have received rTMS for any previous indication due to the potential compromise of subject blinding.